Advances in therapeutics for neurodegenerative tauopathies: Moving toward the specific targeting of the most toxic tau species

ACS Chemical Neuroscience

Volumn 5, Issue 9, 2014, Pages 752-769

  Gerson, Julia E ^a   Castillo Carranza, Diana L ^a   Kayed, Rakez ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Immunotherapy; Molecular chaperones; Oligomers; Small molecules

Indexed keywords

AMYLOID PROTEIN; CHAPERONE; CYSTEINE; DAUNORUBICIN; DOXORUBICIN; FK 506 BINDING PROTEIN; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE 6; HYDROXYTYROSOL; MASITINIB; NEUROTROPHIN RECEPTOR P75; OLEUROPEIN; OLIGOMER; OLIVE OIL; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN TYROSINE KINASE; RESVERATROL; SARACATINIB; STAUROSPORINE; TAU PROTEIN; THIOL GROUP; ANTIBODY;

ACETYLATION; ACTIVE IMMUNIZATION; ALTERNATIVE RNA SPLICING; AMYLOIDOSIS; BRAIN HOMOGENATE; COGNITIVE DEFECT; ENZYME INHIBITION; HUMAN; IMMUNOTHERAPY; NERVE DEGENERATION; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN HOMEOSTASIS; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN TARGETING; REVIEW; SUMOYLATION; TAUOPATHY; ANIMAL; CHEMISTRY; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM; NEURODEGENERATIVE DISEASES; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES; HUMANS; NEURODEGENERATIVE DISEASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; TAU PROTEINS;

EID: 84924980333     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn500143n     Document Type: Review

References (274)

1. Ballatore, C., Lee, V. M., and Trojanowski, J. Q. (2007) Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci 8, 663-672.
2. Rapoport, M., Dawson, H. N., Binder, L. I., Vitek, M. P., and Ferreira, A. (2002) Tau is essential to β-amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. U.S.A. 99, 6364-6369.
3. Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., and Mucke, L. (2007) Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science 316, 750-754.
4. Vossel, K. A., Zhang, K., Brodbeck, J., Daub, A. C., Sharma, P., Finkbeiner, S., Cui, B., and Mucke, L. (2010) Tau reduction prevents Aβ-induced defects in axonal transport. Science 330, 198.
5. Roberson, E. D., Halabisky, B., Yoo, J. W., Yao, J., Chin, J., Yan, F., Wu, T., Hamto, P., Devidze, N., Yu, G.-Q., Palop, J. J., Noebels, J. L., and Mucke, L. (2011) Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J. Neurosci. 31, 700-711.
6. Shipton, O. A., Leitz, J. R., Dworzak, J., Acton, C. E. J., Tunbridge, E. M., Denk, F., Dawson, H. N., Vitek, M. P., Wade-Martins, R., Paulsen, O., and Vargas-Caballero, M. (2011) Tau protein is required for amyloid β-induced impairment of hippocampal long-term potentiation. J. Neurosci. 31, 1688-1692.
7. Abbondante, S., Baglietto-Vargas, D., Rodriguez-Ortiz, C. J., Estrada-Hernandez, T., Medeiros, R., and LaFerla, F. M. (2014) Genetic ablation of tau mitigates cognitive impairment induced by type 1 diabetes. Am. J. Pathol. 184, 819-826.
8. Holth, J. K., Bomben, V. C., Reed, J. G., Inoue, T., Younkin, L., Younkin, S. G., Pautler, R. G., Botas, J., and Noebels, J. L. (2013) Tau loss attenuates neuronal network hyperexcitability in mouse and drosophila genetic models of epilepsy. J. Neurosci. 33, 1651-1659.
9. DeVos, S. L., Goncharoff, D. K., Chen, G., Kebodeaux, C. S., Yamada, K., Stewart, F. R., Schuler, D. R., Maloney, S. E., Wozniak, D. F., Rigo, F., Bennett, C. F., Cirrito, J. R., Holtzman, D. M., and Miller, T. M. (2013) Antisense reduction of tau in adult mice protects against seizures. J. Neurosci. 33, 12887-12897.
10. Iqbal, K., Liu, F., and Gong, C.-X. (2014) Alzheimer disease therapeutics: focus on the disease and not just plaques and tangles. Biochem. Pharmacol. 88, 631-639.
11. Morris, M., Hamto, P., Adame, A., Devidze, N., Masliah, E., and Mucke, L. (2013) Age-appropriate cognition and subtle dopamine-independent motor deficits in aged Tau knockout mice. Neurobiol. Aging 34, 1523-1529.
12. Harada, A., Oguchi, K., Okabe, S., Kuno, J., Terada, S., Ohshima, T., Sato-Yoshitake, R., Takei, Y., Noda, T., and Hirokawa, N. (1994) Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature 369, 488-491.
13. Dawson, H. N., Ferreira, A., Eyster, M. V., Ghoshal, N., Binder, L. I., and Vitek, M. P. (2001) Inhibition of neuronal maturation in primary hippocampal neurons from τ deficient mice. J. Cell Sci. 114, 1179-1187.
14. Dawson, H. N., Cantillana, V., Jansen, M., Wang, H., Vitek, M. P., Wilcock, D. M., Lynch, J. R., and Laskowitz, D. T. (2010) Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease. Neuroscience 169, 516-531.
15. Bolkan, B. J., and Kretzschmar, D. (2014) Loss of tau results in defects in photoreceptor development and progressive neuronal degeneration in Drosophila . Dev. Neurobiol., DOI: 10.1002/dneu.22199.
16. Lei, P., Ayton, S., Finkelstein, D. I., Spoerri, L., Ciccotosto, G. D., Wright, D. K., Wong, B. X. W., Adlard, P. A., Cherny, R. A., Lam, L. Q., Roberts, B. R., Volitakis, I., Egan, G. F., McLean, C. A., Cappai, R., Duce, J. A., and Bush, A. I. (2012) Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat. Med. 18, 291-295.
17. Drubin, D. G., and Kirschner, M. W. (1986) Tau protein function in living cells. J. Cell Biol. 103, 2739-2746.
18. Binder, L. I., Frankfurter, A., and Rebhun, L. I. (1985) Distribution of tau in the mammalian central nervous system. J. Cell Biol. 101, 1371-1378.
19. Sapir, T., Frotscher, M., Levy, T., Mandelkow, E.-M., and Reiner, O. (2012) Tau's role in the developing brain: implications for intellectual disability. Hum. Mol. Genet. 21, 1681-1692.
20. Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., and Crowther, R. A. (1989) Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3, 519-526.
21. Gomez-Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., and Hyman, B. T. (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 41, 17-24.
22. Terry, R. D. (2000) Do neuronal inclusions kill the cell? J. Neural Transm., Suppl. 59, 91-93.
23. van de Nes, J. A., Nafe, R., and Schlote, W. (2008) Non-tau based neuronal degeneration in Alzheimer's disease - an immunocytochemical and quantitative study in the supragranular layers of the middle temporal neocortex. Brain Res. 1213, 152-165.
24. Vogt, B. A., Vogt, L. J., Vrana, K. E., Gioia, L., Meadows, R. S., Challa, V. R., Hof, P. R., and Van Hoesen, G. W. (1998) Multivariate analysis of laminar patterns of neurodegeneration in posterior cingulate cortex in Alzheimer's disease. Exp. Neurol. 153, 8-22.
25. Kuchibhotla, K. V., Wegmann, S., Kopeikina, K. J., Hawkes, J., Rudinskiy, N., Andermann, M. L., Spires-Jones, T. L., Bacskai, B. J., and Hyman, B. T. (2014) Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo. Proc. Natl. Acad. Sci. U.S.A. 111, 510-514.
26. Rudinskiy, N., Hawkes, J., Wegmann, S., Kuchibhotla, K., Muzikansky, A., Betensky, R., Spires-Jones, T., and Hyman, B. (2014) Tau pathology does not affect experience-driven single-neuron and network-wide Arc/Arg3.1 responses. Acta Neuropathol. Commun. 2, 63.
27. Andorfer, C., Kress, Y., Espinoza, M., de Silva, R., Tucker, K. L., Barde, Y. A., Duff, K., and Davies, P. (2003) Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem. 86, 582-590.
28. Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S. M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., and Lee, V. M. (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337-351.
29. Spires, T. L., Orne, J. D., SantaCruz, K., Pitstick, R., Carlson, G. A., Ashe, K. H., and Hyman, B. T. (2006) Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am. J. Pathol. 168, 1598-1607.
30. SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., Forster, C., Yue, M., Orne, J., Janus, C., Mariash, A., Kuskowski, M., Hyman, B., Hutton, M., and Ashe, K. H. (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481.
31. Berger, Z., Roder, H., Hanna, A., Carlson, A., Rangachari, V., Yue, M., Wszolek, Z., Ashe, K., Knight, J., Dickson, D., Andorfer, C., Rosenberry, T. L., Lewis, J., Hutton, M., and Janus, C. (2007) Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J. Neurosci. 27, 3650-3662.
32. Wittmann, C. W., Wszolek, M. F., Shulman, J. M., Salvaterra, P. M., Lewis, J., Hutton, M., and Feany, M. B. (2001) Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 293, 711-714.
33. Cowan, C. M., Bossing, T., Page, A., Shepherd, D., and Mudher, A. (2010) Soluble hyper-phosphorylated tau causes microtubule breakdown and functionally compromises normal tau in vivo. Acta Neuropathol. 120, 593-604.
34. Maeda, S., Sahara, N., Saito, Y., Murayama, M., Yoshiike, Y., Kim, H., Miyasaka, T., Murayama, S., Ikai, A., and Takashima, A. (2007) Granular tau oligomers as intermediates of tau filaments. Biochemistry 46, 3856-3861.
35. Maeda, S., Sahara, N., Saito, Y., Murayama, S., Ikai, A., and Takashima, A. (2006) Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease. Neurosci. Res. 54, 197-201.
36. Patterson, K. R., Remmers, C., Fu, Y., Brooker, S., Kanaan, N. M., Vana, L., Ward, S., Reyes, J. F., Philibert, K., Glucksman, M. J., and Binder, L. I. (2011) Characterization of prefibrillar tau oligomers in vitro and in Alzheimers disease. J. Biol. Chem. 286, 23063-23076.
37. Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Sengupta, U., Sarmiento, J., Troncoso, J., Jackson, G. R., and Kayed, R. (2012) Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J. 26, 1946-1959.
38. Gerson, J., Sengupta, U., Lasagna-Reeves, C., Guerrero-Munoz, M., Troncoso, J., and Kayed, R. (2014) Characterization of tau oligomeric seeds in progressive supranuclear palsy. Acta Neuropathol. Commun. 2, 73.
39. Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Sengupta, U., Clos, A. L., Jackson, G. R., and Kayed, R. (2011) Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wildtype mice. Mol. Neurodegener. 6, 39.
40. Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., and Binder, L. I. (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U.S.A. 83, 4913-4917.
41. Lee, V. M. Y., Balin, B. J., Otvos, L., Jr., and Trojanowski, J. Q. (1991) A68: a major subunit of paired helical filaments and derivatized forms of normal tau. Science 251, 675-678.
42. von Bergen, M., Barghorn, S., Biernat, J., Mandelkow, E.-M., and Mandelkow, E. (2005) Tau aggregation is driven by a transition from random coil to beta sheet structure. Biochim. Biophys. Acta, Mol. Basis Dis. 1739, 158-166.
43. Margittai, M., and Langen, R. (2004) Template-assisted filament growth by parallel stacking of tau. Proc. Natl. Acad. Sci. U.S.A. 101, 10278-10283.
44. Wille, H., Drewes, G., Biernat, J., Mandelkow, E. M., and Mandelkow, E. (1992) Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro. J. Cell Biol. 118, 573-584.
45. King, M. E., Ahuja, V., Binder, L. I., and Kuret, J. (1999) Ligand-dependent tau filament formation: implications for Alzheimer's disease progression. Biochemistry 38, 14851-14859.
46. Wilson, D. M., and Binder, L. I. (1997) Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease. Am. J. Pathol. 150, 2181-2195.
47. King, M. E., Gamblin, T. C., Kuret, J., and Binder, L. I. (2000) Differential assembly of human tau isoforms in the presence of arachidonic acid. J. Neurochem. 74, 1749-1757.
48. Chirita, C. N., Necula, M., and Kuret, J. (2003) Anionic micelles and vesicles induce tau fibrillization in vitro. J. Biol. Chem. 278, 25644-25650.
49. Barghorn, S., and Mandelkow, E. (2002) Toward a unified scheme for the aggregation of tau into Alzheimer paired helical filaments. Biochemistry 41, 14885-14896.
50. Serio, T. R., Cashikar, A. G., Kowal, A. S., Sawicki, G. J., Moslehi, J. J., Serpell, L., Arnsdorf, M. F., and Lindquist, S. L. (2000) Nucleated conformational conversion and the replication of conformational information by a prion determinant. Science 289, 1317-1321.
51. Lee, J., Culyba, E. K., Powers, E. T., and Kelly, J. W. (2011) Amyloid-beta forms fibrils by nucleated conformational conversion of oligomers. Nat. Chem. Biol. 7, 602-609.
52. Ruschak, A. M., and Miranker, A. D. (2009) The role of prefibrillar structures in the assembly of a peptide amyloid. J. Mol. Biol. 393, 214-226.
53. Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Guerrero-Muoz, M. J., Jackson, G. R., and Kayed, R. (2010) Preparation and characterization of neurotoxic tau oligomers. Biochemistry 49, 10039-10041.
54. Sahara, N., Maeda, S., Murayama, M., Suzuki, T., Dohmae, N., Yen, S.-H., and Takashima, A. (2007) Assembly of two distinct dimers and higher-order oligomers from full-length tau. Eur. J. Neurosci. 25, 3020-3029.
55. Chirita, C. N., Congdon, E. E., Yin, H., and Kuret, J. (2005) Triggers of full-length tau aggregation: a role for partially folded intermediates. Biochemistry 44, 5862-5872.
56. Wu, J. W., Herman, M., Liu, L., Simoes, S., Acker, C. M., Figueroa, H., Steinberg, J. I., Margittai, M., Kayed, R., Zurzolo, C., Di Paolo, G., and Duff, K. E. (2013) Small misfolded tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J. Biol. Chem. 288, 1856-1870.
57. Lasagna-Reeves, C., Castillo-Carranza, D. L., Sengupta, U., Guerrero-Munoz, M. J., Kiritoshi, T., Neugebauer, V., Jackson, G. R., and Kayed, R. (2012) Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci. Rep. 2, 1-7.
58. Gerson, J. E., and Kayed, R. (2013) Formation and propagation of tau oligomeric seeds. Front. Neurol. 4, 93.
59. Guerrero-Muñoz, M. J., Castillo-Carranza, D. L., and Kayed, R. (2014) Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins. Biochem. Pharmacol. 88, 468-478.
60. Castillo-Carranza, D. L., Lasagna-Reeves, C. A., and Kayed, R. (2013) Tau aggregates as immunotherapeutic targets. Front. Biosci., Scholar Ed. 5, 426-438.
61. Hartl, F. U., Bracher, A., and Hayer-Hartl, M. (2011) Molecular chaperones in protein folding and proteostasis. Nature 475, 324-332.
62. Sahara, N., Murayama, M., Mizoroki, T., Urushitani, M., Imai, Y., Takahashi, R., Murata, S., Tanaka, K., and Takashima, A. (2005) In vivo evidence of CHIP up-regulation attenuating tau aggregation. J. Neurochem. 94, 1254-1263.
63. Hamos, J. E. (1991) Expression of heat shock proteins in Alzheimer's disease. Neurology 41, 345-350.
64. Perez, N., Sugar, J., Charya, S., Johnson, G., Merril, C., Bierer, L., Perl, D., Haroutunian, V., and Wallace, W. (1991) Increased synthesis and accumulation of heat shock 70 proteins in Alzheimer's disease. Mol. Brain Res. 11, 249-254.
65. Rüdiger, S., Buchberger, A., and Bukau, B. (1997) Interaction of Hsp70 chaperones with substrates. Nat. Struct. Biol. 4, 342-349.
66. Pearl, L. H., and Prodromou, C. (2006) Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu. Rev. Biochem. 75, 271-294.
67. Jiang, J., Ballinger, C. A., Wu, Y., Dai, Q., Cyr, D. M., Höhfeld, J., and Patterson, C. (2001) CHIP is a U-box-dependent E3 ubiquitin ligase: identification of Hsc70 as a target for ubiquitylation. J. Biol. Chem. 276, 42938-42944.
68. Ballinger, C. A., Connell, P., Wu, Y., Hu, Z., Thompson, L. J., Yin, L.-Y., and Patterson, C. (1999) Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol. Cell. Biol. 19, 4535-4545.
69. Petrucelli, L., Dickson, D., Kehoe, K., Taylor, J., Snyder, H., Grover, A., De Lucia, M., McGowan, E., Lewis, J., Prihar, G., Kim, J., Dillmann, W. H., Browne, S. E., Hall, A., Voellmy, R., Tsuboi, Y., Dawson, T. M., Wolozin, B., Hardy, J., and Hutton, M. (2004) CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet. 13, 703-714.
70. Dou, F., Netzer, W. J., Tanemura, K., Li, F., Hartl, F. U., Takashima, A., Gouras, G. K., Greengard, P., and Xu, H. (2003) Chaperones increase association of tau protein with microtubules. Proc. Natl. Acad. Sci. U.S.A. 100, 721-726.
71. Dickey, C. A., Yue, M., Lin, W.-L., Dickson, D. W., Dunmore, J. H., Lee, W. C., Zehr, C., West, G., Cao, S., Clark, A. M. K., Caldwell, G. A., Caldwell, K. A., Eckman, C., Patterson, C., Hutton, M., and Petrucelli, L. (2006) Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phosphoand caspase-3-cleaved tau species. J. Neurosci. 26, 6985-6996.
72. Cook, C., and Petrucelli, L. (2013) Tau triage decisions mediated by the chaperone network. J. Alzheimer's Dis. 33, S145-S151.
73. Cook, C., Gendron, T. F., Scheffel, K., Carlomagno, Y., Dunmore, J., DeTure, M., and Petrucelli, L. (2012) Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation. Hum. Mol. Genet. 21, 2936-2945.
74. Selenica, M.-L., Benner, L., Housley, S., Manchec, B., Lee, D., Nash, K., Kalin, J., Bergman, J., Kozikowski, A., Gordon, M., and Morgan, D. (2014) Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition. Alzheimer's Res. Ther. 6, 12.
75. Shimura, H., Miura-Shimura, Y., and Kosik, K. S. (2004) Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival. J. Biol. Chem. 279, 17957-17962.
76. Karagöz, G. E., Duarte, A. M. S., Akoury, E., Ippel, H., Biernat, J., Morán Luengo, T., Radli, M., Didenko, T., Nordhues, B. A., Veprintsev, D. B., Dickey, C. A., Mandelkow, E., Zweckstetter, M., Boelens, R., Madl, T., and Rüdiger, S. G. D. (2014) Hsp90-tau complex reveals molecular basis for specificity in chaperone action. Cell 156, 963-974.
77. Dickey, C. A., Dunmore, J., Lu, B., Wang, J.-W., Lee, W. C., Kamal, A., Burrows, F., Eckman, C., Hutton, M., and Petrucelli, L. (2006) HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB J. 20, 753-755.
78. Dickey, C. A., Kamal, A., Lundgren, K., Klosak, N., Bailey, R. M., Dunmore, J., Ash, P., Shoraka, S., Zlatkovic, J., Eckman, C. B., Patterson, C., Dickson, D. W., Nahman, N. S., Jr., Hutton, M., Burrows, F., and Petrucelli, L. (2007) The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J. Clin. Invest. 117, 648-658.
79. Opattova, A., Filipcik, P., Cente, M., and Novak, M. (2013) Intracellular degradation of misfolded tau protein induced by geldanamycin is associated with activation of proteasome. J. Alzheimer's Dis. 33, 339-348.
80. Dou, F., Yuan, L.-D., and Zhu, J.-J. (2005) Heat shock protein 90 indirectly regulates ERK activity by affecting raf protein metabolism. Acta Biochim. Biophys. Sin. 37, 501-505.
81. Kitson, R. R. A., and Moody, C. J. (2013) An improved route to 19-substituted geldanamycins as novel Hsp90 inhibitors - potential therapeutics in cancer and neurodegeneration. Chem. Commun. 49, 8441-8443.
82. Dickey, C. A., Koren, J., Zhang, Y.-J., Xu, Y.-f., Jinwal, U. K., Birnbaum, M. J., Monks, B., Sun, M., Cheng, J. Q., Patterson, C., Bailey, R. M., Dunmore, J., Soresh, S., Leon, C., Morgan, D., and Petrucelli, L. (2008) Akt and CHIP coregulate tau degradation through coordinated interactions. Proc. Natl. Acad. Sci. U.S.A. 105, 3622-3627.
83. Sinadinos, C., Quraishe, S., Sealey, M., Samson, P. B., Mudher, A., and Wyttenbach, A. (2013) Low endogenous and chemical induced heat shock protein induction in a 0N3Rtau-expressing Drosophila larval model of Alzheimer's disease. J. Alzheimer's Dis. 33, 1117-1133.
84. Chen, Y., Wang, B., Liu, D., Li, J. J., Xue, Y., Sakata, K., Zhu, L.-q., Heldt, S. A., Xu, H., and Liao, F.-F. (2014) Hsp90 chaperone inhibitor 17-AAG attenuates Aβ-induced synaptic toxicity and memory impairment. J. Neurosci. 34, 2464-2470.
85. Li, C., Ma, J., Zhao, H., Blagg, B. S. J., and Dobrowsky, R. T. (2012) Induction of heat shock protein 70 (Hsp70) prevents neuregulin-induced demyelination by enhancing the proteasomal clearance of c-Jun. ASN Neuro 4, No. e00102.
86. Lu, Y., Ansar, S., Michaelis, M. L., and Blagg, B. S. J. (2009) Neuroprotective activity and evaluation of Hsp90 inhibitors in an immortalized neuronal cell line. Bioorg. Med. Chem. 17, 1709-1715.
87. Ansar, S., Burlison, J. A., Hadden, M. K., Yu, X. M., Desino, K. E., Bean, J., Neckers, L., Audus, K. L., Michaelis, M. L., and Blagg, B. S. J. (2007) A non-toxic Hsp90 inhibitor protects neurons from Aβ-induced toxicity. Bioorg. Med. Chem. Lett. 17, 1984-1990.
88. Blair, L. J., Nordhues, B. A., Hill, S. E., Scaglione, K. M., O'Leary, J. C., III, Fontaine, S. N., Breydo, L., Zhang, B., Li, P., Wang, L., Cotman, C., Paulson, H. L., Muschol, M., Uversky, V. N., Klengel, T., Binder, E. B., Kayed, R., Golde, T. E., Berchtold, N., and Dickey, C. A. (2013) Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. J. Clin. Invest. 123, 4158-4169.
89. Kim, H. R., Kang, H. S., and Kim, H. D. (1999) Geldanamycin induces heat shock protein expression through activation of HSF1 in K562 erythroleukemic cells. IUBMB Life 48, 429-433.
90. Westerheide, S. D., and Morimoto, R. I. (2005) Heat shock response modulators as therapeutic tools for diseases of protein conformation. J. Biol. Chem. 280, 33097-33100.
91. Jiang, Y.-Q., Wang, X.-L., Cao, X.-H., Ye, Z.-Y., Li, L., and Cai, W.-Q. (2013) Increased heat shock transcription factor 1 in the cerebellum reverses the deficiency of purkinje cells in Alzheimer's disease. Brain Res. 1519, 105-111.
92. Jinwal, U. K., Koren, J., III, and Dickey, CA (2013) Reconstructing the Hsp90/tau machine. Curr. Enzyme Inhib. 9, 41-45.
93. Jinwal, U. K., Koren, J., III, Borysov, S. I., Schmid, A. B., Abisambra, J. F., Blair, L. J., Johnson, A. G., Jones, J. R., Shults, C. L., O'Leary, J. C., Jin, Y., Buchner, J., Cox, M. B., and Dickey, C. A. (2010) The Hsp90 cochaperone, FKBP51, increases tau stability and polymerizes microtubules. J. Neurosci. 30, 591-599.
94. Carrettiero, D. C., Hernandez, I., Neveu, P., Papagiannakopoulos, T., and Kosik, K. S. (2009) The cochaperone BAG2 sweeps paired helical filament-insoluble tau from the microtubule. J. Neurosci. 29, 2151-2161.
95. Thompson, A. D., Scaglione, K. M., Prensner, J., Gillies, A. T., Chinnaiyan, A., Paulson, H. L., Jinwal, U. K., Dickey, C. A., and Gestwicki, J. E. (2012) Analysis of the tau-associated proteome reveals that exchange of Hsp70 for Hsp90 is involved in tau degradation. ACS Chem. Biol. 7, 1677-1686.
96. Voss, K., Combs, B., Patterson, K. R., Binder, L. I., and Gamblin, T. C. (2012) Hsp70 alters tau function and aggregation in an isoform specific manner. Biochemistry 51, 888-898.
97. Patterson, K. R., Ward, S. M., Combs, B., Voss, K., Kanaan, N. M., Morfini, G., Brady, S. T., Gamblin, T. C., and Binder, L. I. (2011) Heat shock protein 70 prevents both tau aggregation and the inhibitory effects of preexisting tau aggregates on fast axonal transport. Biochemistry 50, 10300-10310.
98. Miyata, Y., Li, X., Lee, H.-F., Jinwal, U. K., Srinivasan, S. R., Seguin, S. P., Young, Z. T., Brodsky, J. L., Dickey, C. A., Sun, D., and Gestwicki, J. E. (2013) Synthesis and initial evaluation of YM-08, a blood-brain barrier permeable derivative of the heat shock protein 70 (Hsp70) inhibitor MKT-077, which reduces tau levels. ACS Chem. Neurosci. 4, 930-939.
99. Miyata, Y., Rauch, J. N., Jinwal, U. K., Thompson, A. D., Srinivasan, S., Dickey, C. A., and Gestwicki, J. E. (2012) Cysteine reactivity distinguishes redox sensing by the heat-inducible and constitutive forms of heat shock protein 70. Chem. Biol. 19, 1391-1399.
100. Congdon, E. E., Wu, J. W., Myeku, N., Figueroa, Y. H., Herman, M., Marinec, P. S., Gestwicki, J. E., Dickey, C. A., Yu, W. H., and Duff, K. E. (2012) Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy 8, 609-622.
101. Jinwal, U. K., Miyata, Y., Koren, J., III, Jones, J. R., Trotter, J. H., Chang, L., O'Leary, J., Morgan, D., Lee, D. C., Shults, C. L., Rousaki, A., Weeber, E. J., Zuiderweg, E. R. P., Gestwicki, J. E., and Dickey, C. A. (2009) Chemical manipulation of Hsp70 ATPase activity regulates tau stability. J. Neurosci. 29, 12079-12088.
102. Jinwal, U. K., Akoury, E., Abisambra, J. F., O'Leary, J. C., Thompson, A. D., Blair, L. J., Jin, Y., Bacon, J., Nordhues, B. A., Cockman, M., Zhang, J., Li, P., Zhang, B., Borysov, S., Uversky, V. N., Biernat, J., Mandelkow, E., Gestwicki, J. E., Zweckstetter, M., and Dickey, C. A. (2013) Imbalance of Hsp70 family variants fosters tau accumulation. FASEB J. 27, 1450-1459.
103. Abisambra, J., Jinwal, U. K., Miyata, Y., Rogers, J., Blair, L., Li, X., Seguin, S. P., Wang, L., Jin, Y., Bacon, J., Brady, S., Cockman, M., Guidi, C., Zhang, J., Koren, J., III, Young, Z. T., Atkins, C. A., Zhang, B., Lawson, L. Y., Weeber, E. J., Brodsky, J. L., Gestwicki, J. E., and Dickey, C. A. (2013) Allosteric Heat Shock Protein 70 Inhibitors Rapidly Rescue Synaptic Plasticity Deficits by Reducing Aberrant Tau. Biol. Psychiatry 74, 367-374.
104. Abisambra, J. F., Jinwal, U. K., Suntharalingam, A., Arulselvam, K., Brady, S., Cockman, M., Jin, Y., Zhang, B., and Dickey, C. A. (2012) DnaJA1 antagonizes constitutive Hsp70-mediated stabilization of tau. J. Mol. Biol. 421, 653-661.
105. Shorter, J., and Lindquist, S. (2004) Hsp104 catalyzes formation and elimination of self-replicating Sup35 prion conformers. Science 304, 1793-1797.
106. Shorter, J., and Lindquist, S. (2006) Destruction or potentiation of different prions catalyzed by similar Hsp104 remodeling activities. Mol. Cell 23, 425-438.
107. Lo Bianco, C., Shorter, J., Régulier, E., Lashuel, H., Iwatsubo, T., Lindquist, S., and Aebischer, P. (2008) Hsp104 antagonizes α-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. J. Clin. Invest. 118, 3087-3097.
108. Vashist, S., Cushman, M., and Shorter, J. (2010) Applying Hsp104 to protein-misfolding disorders. Biochem. Cell Biol. 88, 1-13.
109. DeSantis, M. E., Leung, E. H., Sweeny, E. A., Jackrel, M. E., Cushman-Nick, M., Neuhaus-Follini, A., Vashist, S., Sochor, M. A., Knight, M. N., and Shorter, J. (2012) Operational plasticity enables Hsp104 to disaggregate diverse amyloid and nonamyloid clients. Cell 151, 778-793.
110. Wang, Y., Martinez-Vicente, M., Krüger, U., Kaushik, S., Wong, E., Mandelkow, E.-M., Cuervo, A. M., and Mandelkow, E. (2009) Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing. Hum. Mol. Genet. 18, 4153-4170.
111. Krüger, U., Wang, Y., Kumar, S., and Mandelkow, E.-M. (2012) Autophagic degradation of tau in primary neurons and its enhancement by trehalose. Neurobiol. Aging 33, 2291-2305.
112. Andreu, C. I., Woehlbier, U., Torres, M., and Hetz, C. (2012) Protein disulfide isomerases in neurodegeneration: from disease mechanisms to biomedical applications. FEBS Lett. 586, 2826-2834.
113. Honjo, Y., Ito, H., Horibe, T., Takahashi, R., and Kawakami, K. (2010) Protein disulfide isomerase-immunopositive inclusions in patients with Alzheimer disease. Brain Res. 1349, 90-96.
114. Xu, L.-R., Liu, X.-L., Chen, J., and Liang, Y. (2013) Protein disulfide isomerase interacts with tau protein and inhibits its fibrillization. PLoS One 8, e76657.
115. Ali, Y. O., Ruan, K., and Zhai, R. G. (2012) NMNAT suppresses tau-induced neurodegeneration by promoting clearance of hyperphosphorylated tau oligomers in a Drosophila model of tauopathy. Hum. Mol. Genet. 21, 237-250.
116. Porat, Y., Abramowitz, A., and Gazit, E. (2006) Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem. Biol. Drug Des. 67, 27-37.
117. Jinwal, U., Miyata, Y., Koren, J., III, Jones, J., Trotter, J., Chang, L., O'Leary, J., Morgan, D., Lee, D., Shults, C., Rousaki, A., Weeber, E., Zuiderweg, E., Gestwicki, J., and Dickey, C. (2009) Chemical manipulation of hsp70 ATPase activity regulates tau stability. J. Neurosci. 29, 12079-12088.
118. Huang, H.-C., Tang, D., Xu, K., and Jiang, Z.-F. (2014) Curcumin attenuates amyloid-β-induced tau hyperphosphorylation in human neuroblastoma SH-SY5Y cells involving PTEN/Akt/GSK-3β signaling pathway. J. Recept. Signal Transduction 34, 26-37.
119. Hoppe, J. B., Coradini, K., Frozza, R. L., Oliveira, C. M., Meneghetti, A. B., Bernardi, A., Pires, E. S., Beck, R. C. R., and Salbego, C. G. (2013) Free and nanoencapsulated curcumin suppress β-amyloid-induced cognitive impairments in rats: Involvement of BDNF and Akt/GSK-3β signaling pathway. Neurobiol. Learn. Mem. 106, 134-144.
120. Patil, S. P., Tran, N., Geekiyanage, H., Liu, L., and Chan, C. (2013) Curcumin-induced upregulation of the anti-tau cochaperone BAG2 in primary rat cortical neurons. Neurosci. Lett. 554, 121-125.
121. Mohorko, N., Repovš, G., Popovic, M., Kovacs, G. G., and Bresjanac, M. (2010) Curcumin labeling of neuronal fibrillar tau inclusions in human brain samples. J. Neuropathol. Exp. Neurol. 69, 405-414.
122. Ma, Q.-L., Zuo, X., Yang, F., Ubeda, O. J., Gant, D. J., Alaverdyan, M., Teng, E., Hu, S., Chen, P.-P., Maiti, P., Teter, B., Cole, G. M., and Frautschy, S. A. (2013) Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice. J. Biol. Chem. 288, 4056-4065.
123. Purkayastha, S., Berliner, A., Fernando, S. S., Ranasinghe, B., Ray, I., Tariq, H., and Banerjee, P. (2009) Curcumin blocks brain tumor formation. Brain Res. 1266, 130-138.
124. Ringman, J., Frautschy, S., Teng, E., Begum, A., Bardens, J., Beigi, M., Gylys, K., Badmaev, V., Heath, D., Apostolova, L., Porter, V., Vanek, Z., Marshall, G., Hellemann, G., Sugar, C., Masterman, D., Montine, T., Cummings, J., and Cole, G. (2012) Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimer's Res. Ther. 4, 43.
125. Dolai, S., Shi, W., Corbo, C., Sun, C., Averick, S., Obeysekera, D., Farid, M., Alonso, A., Banerjee, P., and Raja, K. (2011) "Clicked"sugar - curcumin conjugate: modulator of amyloid-β and tau peptide aggregation at ultralow concentrations. ACS Chem. Neurosci. 2, 694-699.
126. Narlawar, R., Pickhardt, M., Leuchtenberger, S., Baumann, K., Krause, S., Dyrks, T., Weggen, S., Mandelkow, E., and Schmidt, B. (2008) Curcumin-derived pyrazoles and isoxazoles: swiss army knives or blunt tools for Alzheimer's disease? ChemMedChem. 3, 165-172.
127. Rezai-Zadeh, K., Arendash, G. W., Hou, H., Fernandez, F., Jensen, M., Runfeldt, M., Shytle, R. D., and Tan, J. (2008) Green tea epigallocatechin-3-gallate (EGCG) reduces β-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. Brain Res. 1214, 177-187.
128. Kim, D., Nguyen, M. D., Dobbin, M. M., Fischer, A., Sananbenesi, F., Rodgers, J. T., Delalle, I., Baur, J. A., Sui, G., Armour, S. M., Puigserver, P., Sinclair, D. A., and Tsai, L. H. (2007) SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J. 26, 3169-3179.
129. Julien, C., Tremblay, C., É mond, V., Lebbadi, M., Salem, N. J., Bennett, D. A., and Calon, F. (2009) Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J. Neuropathol. Exp. Neurol. 68, 48-58.
130. Du, L.-L., Xie, J.-Z., Cheng, X.-S., Li, X.-H., Kong, F.-L., Jiang, X., Ma, Z.-W., Wang, J.-Z., Chen, C., and Zhou, X.-W. (2014) Activation of sirtuin 1 attenuates cerebral ventricular streptozotocin-induced tau hyperphosphorylation and cognitive injuries in rat hippocampi. Age 36, 613-623.
131. Lee, H. R., Shin, H. K., Park, S. Y., Kim, H. Y., Lee, W. S., Rhim, B. Y., Hong, K. W., and Kim, C. D. (2014) Attenuation of β-amyloid-induced tauopathy via activation of CK2α/SIRT1: targeting for cilostazol. J. Neurosci. Res. 92, 206-217.
132. Porquet, D., Casadesús, G., Bayod, S., Vicente, A., Canudas, A., Vilaplana, J., Pelegrí, C., Sanfeliu, C., Camins, A., Pallàs, M., and del Valle, J. (2013) Dietary resveratrol prevents Alzheimer's markers and increases life span in SAMP8. Age 35, 1851-1865.
133. Varamini, B., Sikalidis, A. K., and Bradford, K. L. (2013) Resveratrol increases cerebral glycogen synthase kinase phosphorylation as well as protein levels of drebrin and transthyretin in mice: an exploratory study. Int. J. Food Sci. Nutr. 65, 89-96.
134. Marambaud, P., Zhao, H., and Davies, P. (2005) Resveratrol promotes clearance of Alzheimer's disease amyloid-β peptides. J. Biol. Chem. 280, 37377-37382.
135. Ladiwala, A. R. A., Lin, J. C., Bale, S. S., Marcelino-Cruz, A. M., Bhattacharya, M., Dordick, J. S., and Tessier, P. M. (2010) Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Aβ into off-pathway conformers. J. Biol. Chem. 285, 24228-24237.
136. Almeida, L., Vaz-da-Silva, M., Falcão, A., Soares, E., Costa, R., Loureiro, A. I., Fernandes-Lopes, C., Rocha, J.-F., Nunes, T., Wright, L., and Soares-da-Silva, P. (2009) Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol. Nutr. Food Res. 53, S7-S15.
137. Li, W., Sperry, J. B., Crowe, A., Trojanowski, J. Q., Smith Iii, A. B., and Lee, V. M. Y. (2009) Inhibition of tau fibrillization by oleocanthal via reaction with the amino groups of tau. J. Neurochem. 110, 1339-1351.
138. Daccache, A., Lion, C., Sibille, N., Gerard, M., Slomianny, C., Lippens, G., and Cotelle, P. (2011) Oleuropein and derivatives from olives as Tau aggregation inhibitors. Neurochem. Int. 58, 700-707.
139. Wu, Y.-T., Lin, L.-C., and Tsai, T.-H. (2009) Measurement of free hydroxytyrosol in microdialysates from blood and brain of anesthetized rats by liquid chromatography with fluorescence detection. J. Chromatogr. A 1216, 3501-3507.
140. Stamer, K., Vogel, R., Thies, E., Mandelkow, E., and Mandelkow, E.-M. (2002) Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J. Cell Biol. 156, 1051-1063.
141. Blair, L. J., Z, B., and Dickey, C. A. (2013) Potential synergy between tau aggregation inhibitors and tau chaperone modulators. Alzheimer's Res. Ther. 5, 41.
142. Caughey, W. S., Raymond, L. D., Horiuchi, M., and Caughey, B. (1998) Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. Proc. Natl. Acad. Sci. U.S.A. 95, 12117-12122.
143. Park, J.-W., Ahn, J. S., Lee, J.-H., Bhak, G., Jung, S., and Paik, S. R. (2008) Amyloid fibrillar meshwork formation of iron-induced oligomeric species of Aβ40 with phthalocyanine tetrasulfonate and its toxic consequences. ChemBioChem 9, 2602-2605.
144. Taniguchi, S., Suzuki, N., Masuda, M., Hisanaga, S., Iwatsubo, T., Goedert, M., and Hasegawa, M. (2005) Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem. 280, 7614-7623.
145. Akoury, E., Gajda, M., Pickhardt, M., Biernat, J., Soraya, P., Griesinger, C., Mandelkow, E., and Zweckstetter, M. (2013) Inhibition of tau filament formation by conformational modulation. J. Am. Chem. Soc. 135, 2853-2862.
146. Snow, A. D., Cummings, J., Lake, T., Hu, Q., Esposito, L., Cam, J., Hudson, M., Smith, E., and Runnels, S. (2009) Exebryl-1: a novel small molecule currently in human clinical trials as a disease-modifying drug for the treatment of Alzheimer's disease. Alzheimer's Dementia 5, P418.
147. Song, J. M., DiBattista, A. M., Sung, Y. M., Ahn, J. M., Turner, R. S., Yang, J., Pak, D. T. S., Lee, H.-K., and Hoe, H.-S. (2014) A tetra(ethylene glycol) derivative of benzothiazole aniline ameliorates dendritic spine density and cognitive function in a mouse model of Alzheimer's disease. Exp. Neurol. 252, 105-113.
148. Akoury, E., Pickhardt, M., Gajda, M., Biernat, J., Mandelkow, E., and Zweckstetter, M. (2013) Mechanistic basis of phenothiazine-driven inhibition of tau aggregation. Angew. Chem., Int. Ed. 52, 3511-3515.
149. Crowe, A., James, M. J., Lee, V. M.-Y., Smith, A. B., Trojanowski, J. Q., Ballatore, C., and Brunden, K. R. (2013) Aminothienopyridazines and methylene blue affect tau fibrillization via cysteine oxidation. J. Biol. Chem. 288, 11024-11037.
150. Hattori, M., Sugino, E., Minoura, K., In, Y., Sumida, M., Taniguchi, T., Tomoo, K., and Ishida, T. (2008) Different inhibitory response of cyanidin and methylene blue for filament formation of tau microtubule-binding domain. Biochem. Biophys. Res. Commun. 374, 158-163.
151. Hosokawa, M., Arai, T., Masuda-Suzukake, M., Nonaka, T., Yamashita, M., Akiyama, H., and Hasegawa, M. (2012) Methylene blue reduced abnormal tau accumulation in P301L tau transgenic mice. PLoS One 7, e52389.
152. Fatouros, C., Pir, G. J., Biernat, J., Koushika, S. P., Mandelkow, E., Mandelkow, E.-M., Schmidt, E., and Baumeister, R. (2012) Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity. Hum. Mol. Genet. 21, 3587-3603.
153. van Bebber, F., Paquet, D., Hruscha, A., Schmid, B., and Haass, C. (2010) Methylene blue fails to inhibit tau and polyglutamine protein dependent toxicity in zebrafish. Neurobiol. Dis. 39, 265-271.
154. Spires-Jones, T. L., Friedman, T., Pitstick, R., Polydoro, M., Roe, A., Carlson, G. A., and Hyman, B. T. (2014) Methylene blue does not reverse existing neurofibrillary tangle pathology in the rTg4510 mouse model of tauopathy. Neurosci. Lett. 562, 63-68.
155. O'Leary, J., Li, Q., Marinec, P., Blair, L., Congdon, E., Johnson, A., Jinwal, U., Koren, J., Jones, J., Kraft, C., Peters, M., Abisambra, J., Duff, K., Weeber, E., Gestwicki, J., and Dickey, C. (2010) Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Mol. Neurodegener. 5, 45.
156. Stack, C., Jainuddin, S., Elipenahli, C., Gerges, M., Starkova, N., Starkov, A. A., Jové, M., Portero-Otin, M., Launay, N., Pujol, A., Kaidery, N. A., Thomas, B., Tampellini, D., Beal, M. F., and Dumont, M. (2014) Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity. Hum. Mol. Genet. 23, 3716-3732.
157. Medina, D. X., Caccamo, A., and Oddo, S. (2011) Methylene blue reduces Aβ levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol. 21, 140-149.
158. T, G. (2008) Hope in Alzheimer's fight emerges from unexpected places. Nat. Med. 14, 894.
159. Khlistunova, I., Biernat, J., Wang, Y., Pickhardt, M., von Bergen, M., Gazova, Z., Mandelkow, E., and Mandelkow, E.-M. (2006) Inducible expression of tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J. Biol. Chem. 281, 1205-1214.
160. Pickhardt, M., B, J., Khlistunova, I., Wang, Y. P., Gazova, Z., Mandelkow, E. M., and Mandelkow, E. (2007) N-Phenylamine derivatives as aggregation inhibitors in cell models of tauopathy. Curr. Alzheimer Res. 4, 397-402.
161. Pickhardt, M., Larbig, G., Khlistunova, I., Coksezen, A., Meyer, B., Mandelkow, E.-M., Schmidt, B., and Mandelkow, E. (2007) Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of τaggregation and toxicity in vitro and in cells. Biochemistry 46, 10016-10023.
162. Park, H., Kim, M. K., Kim, D. W., Choo, I. L. H., and Chong, Y. (2010) 3D QSAR CoMFA study on phenylthiazolylhydrazide (PTH) derivatives as tau protein aggregation inhibitors. Bull. Korean Chem. Soc. 31, 3838-3841.
163. Pickhardt, M., Gazova, Z., von Bergen, M., Khlistunova, I., Wang, Y., Hascher, A., Mandelkow, E.-M., Biernat, J., and Mandelkow, E. (2005) Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells. J. Biol. Chem. 280, 3628-3635.
164. Ballatore, C., Brunden, K. R., Piscitelli, F., James, M. J., Crowe, A., Yao, Y., Hyde, E., Trojanowski, J. Q., Lee, V. M. Y., and Smith, A. B. (2010) Discovery of brain-penetrant, orally bioavailable amino-thienopyridazine inhibitors of tau aggregation. J. Med. Chem. 53, 3739-3747.
165. Ballatore, C., Crowe, A., Piscitelli, F., James, M., Lou, K., Rossidivito, G., Yao, Y., Trojanowski, J. Q., Lee, V. M. Y., Brunden, K. R., and Smith Iii, A. B. (2012) Aminothienopyridazine inhibitors of tau aggregation: evaluation of structure - activity relationship leads to selection of candidates with desirable in vivo properties. Bioorg. Med. Chem. 20, 4451-4461.
166. Crowe, A., Huang, W., Ballatore, C., Johnson, R. L., Hogan, A.-M. L., Huang, R., Wichterman, J., McCoy, J., Huryn, D., Auld, D. S., Smith, A. B., Inglese, J., Trojanowski, J. Q., Austin, C. P., Brunden, K. R., and Lee, V. M. Y. (2009) Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry 48, 7732-7745.
167. Hotta, N., Akanuma, Y., Kawamori, R., Matsuoka, K., Oka, Y., Shichiri, M., Toyota, T., Nakashima, M., Yoshimura, I., Sakamoto, N., Shigeta, Y., and Group, t. A. S. (2006) Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative aldose reductase inhibitor-diabetes complications trial. Diabetes Care 29, 1538-1544.
168. Bulic, B., Pickhardt, M., Khlistunova, I., Biernat, J., Mandelkow, E.-M., Mandelkow, E., and Waldmann, H. (2007) Rhodanine-based tau aggregation inhibitors in cell models of tauopathy. Angew. Chem., Int. Ed. 46, 9215-9219.
169. Messing, L., Decker, J. M., Joseph, M., Mandelkow, E., and Mandelkow, E.-M. (2013) Cascade of tau toxicity in inducible hippocampal brain slices and prevention by aggregation inhibitors. Neurobiol. Aging 34, 1343-1354.
170. Schweers, O., Mandelkow, E. M., Biernat, J., and Mandelkow, E. (1995) Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments. Proc. Natl. Acad. Sci. U.S.A. 92, 8463-8467.
171. Mo, Z.-Y., Zhu, Y.-Z., Zhu, H.-L., Fan, J.-B., Chen, J., and Liang, Y. (2009) Low micromolar zinc accelerates the fibrillization of human tau via bridging of Cys-291 and Cys-322. J. Biol. Chem. 284, 34648-34657.
172. Daebel, V., Chinnathambi, S., Biernat, J., Schwalbe, M., Habenstein, B., Loquet, A., Akoury, E., Tepper, K., Müller, H., Baldus, M., Griesinger, C., Zweckstetter, M., Mandelkow, E., Vijayan, V., and Lange, A. (2012) β-Sheet core of tau paired helical filaments revealed by solid-state NMR. J. Am. Chem. Soc. 134, 13982-13989.
173. Walker, S., Ullman, O., and Stultz, C. M. (2012) Using intramolecular disulfide bonds in tau protein to deduce structural features of aggregation-resistant conformations. J. Biol. Chem. 287, 9591-9600.
174. Haque, M. M., Kim, D., Yu, Y. H., Lim, S., Kim, D. J., Chang, Y.-T., Ha, H.-H., and Kim, Y. K. (2014) Inhibition of tau aggregation by a rosamine derivative that blocks tau intermolecular disulfide crosslinking. Amyloid, 1-7.
175. Zheng, J., Liu, C., Sawaya, M. R., Vadla, B., Khan, S., Woods, R. J., Eisenberg, D., Goux, W. J., and Nowick, J. S. (2011) Macrocyclic β-sheet peptides that inhibit the aggregation of a tau-protein-derived hexapeptide. J. Am. Chem. Soc. 133, 3144-3157.
176. Schafer, K. N., Cisek, K., Huseby, C. J., Chang, E., and Kuret, J. (2013) Structural determinants of tau aggregation inhibitor potency. J. Biol. Chem. 288, 32599-32611.
177. Cheng, I. H., Scearce-Levie, K., Legleiter, J., Palop, J. J., Gerstein, H., Bien-Ly, N., Puoliväli, J., Lesné, S., Ashe, K. H., Muchowski, P. J., and Mucke, L. (2007) Accelerating amyloid-βfibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J. Biol. Chem. 282, 23818-23828.
178. Martin, L., Latypova, X., and Terro, F. (2011) Posttranslational modifications of tau protein: implications for Alzheimer's disease. Neurochem. Int. 58, 458-471.
179. Schneider, A., Biernat, J., von Bergen, M., Mandelkow, E., and Mandelkow, E. M. (1999) Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 38, 3549-3558.
180. Abraha, A., Ghoshal, N., Gamblin, T. C., Cryns, V., Berry, R. W., Kuret, J., and Binder, L. I. (2000) C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease. J. Cell Sci. 113, 3737-3745.
181. Haase, C., Stieler, J. T., Arendt, T., and Holzer, M. (2004) Pseudophosphorylation of tau protein alters its ability for self-aggregation. J. Neurochem. 88, 1509-1520.
182. Liu, F., Li, B., Tung, E. J., Grundke-Iqbal, I., Iqbal, K., and Gong, C.-X. (2007) Site-specific effects of tau phosphorylation on its microtubule assembly activity and self-aggregation. Eur. J. Neurosci. 26, 3429-3436.
183. Sergeant, N., Bretteville, A., Hamdane, M., Caillet-Boudin, M.-L., Grognet, P., Bombois, S., Blum, D., Delacourte, A., Pasquier, F., Vanmechelen, E., Schraen-Maschke, S., and Buée, L. (2008) Biochemistry of tau in Alzheimer's disease and related neurological disorders. Expert Rev. Proteomics 5, 207-224.
184. Caccamo, A., Oddo, S., Tran, L. X., and LaFerla, F. M. (2007) Lithium reduces tau phosphorylation but not Aβ or working memory deficits in a transgenic model with both plaques and tangles. Am. J. Pathol. 170, 1669-1675.
185. Engel, T., Goñi-Oliver, P., Lucas, J. J., Avila, J., and Hernández, F. (2006) Chronic lithium administration to FTDP-17 tau and GSK-3β overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J. Neurochem. 99, 1445-1455.
186. Nakashima, H., Ishihara, T., Suguimoto, P., Yokota, O., Oshima, E., Kugo, A., Terada, S., Hamamura, T., Trojanowski, J., Lee, V. Y., and Kuroda, S. (2005) Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathol. 110, 547-556.
187. Serenó, L., Coma, M., Rodríguez, M., Sánchez-Ferrer, P., Sánchez, M. B., Gich, I., Agulló, J. M., Pérez, M., Avila, J., Guardia-Laguarta, C., Clarimón, J., Lleó, A., and Gómez-Isla, T. (2009) A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol. Dis. 35, 359-367.
188. Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Wang, L., LaFrancois, J., Feinstein, B., Burns, M., Krishnamurthy, P., Wen, Y., Bhat, R., Lewis, J., Dickson, D., and Duff, K. (2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. U.S.A. 102, 6990-6995.
189. Liu, F., Grundke-Iqbal, I., Iqbal, K., and Gong, C.-X. (2005) Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur. J. Neurosci. 22, 1942-1950.
190. Wang, J.-Z., Grundke-Iqbal, I., and Iqbal, K. (2007) Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur. J. Neurosci. 25, 59-68.
191. Jung, M.-S., Park, J.-H., Ryu, Y. S., Choi, S.-H., Yoon, S.-H., Kwen, M.-Y., Oh, J. Y., Song, W.-J., and Chung, S.-H. (2011) Regulation of RCAN1 protein activity by Dyrk1A protein-mediated phosphorylation. J. Biol. Chem. 286, 40401-40412.
192. Liu, F., Liang, Z., Wegiel, J., Hwang, Y.-W., Iqbal, K., Grundke-Iqbal, I., Ramakrishna, N., and Gong, C.-X. (2008) Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J. 22, 3224-3233.
193. Woods, Y. L., Cohen, P., Becker, W., Jakes, R., Goedert, M., Wang, X., and Proud, C. G. (2001) The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochem. J. 355, 609-615.
194. Shi, J., Zhang, T., Zhou, C., Chohan, M. O., Gu, X., Wegiel, J., Zhou, J., Hwang, Y.-W., Iqbal, K., Grundke-Iqbal, I., Gong, C.-X., and Liu, F. (2008) Increased dosage of Dyrk1A alters alternative splicing factor (ASF)-regulated alternative splicing of tau in down syndrome. J. Biol. Chem. 283, 28660-28669.
195. Yin, X., Jin, N., Gu, J., Shi, J., Zhou, J., Gong, C.-X., Iqbal, K., Grundke-Iqbal, I., and Liu, F. (2012) Dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) modulates serine/arginine-rich protein 55 (SRp55)-promoted tau exon 10 inclusion. J. Biol. Chem. 287, 30497-30506.
196. Ryoo, S.-R., Cho, H.-J., Lee, H.-W., Jeong, H. K., Radnaabazar, C., Kim, Y.-S., Kim, M.-J., Son, M.-Y., Seo, H., Chung, S.-H., and Song, W.-J. (2008) Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down Syndrome and Alzheimer's disease. J. Neurochem. 104, 1333-1344.
197. Ryu, Y. S., Park, S. Y., Jung, M.-S., Yoon, S.-H., Kwen, M.-Y., Lee, S.-Y., Choi, S.-H., Radnaabazar, C., Kim, M.-K., Kim, H., Kim, K., Song, W.-J., and Chung, S.-H. (2010) Dyrk1A-mediated phosphorylation of presenilin 1: a functional link between Down Syndrome and Alzheimer's disease. J. Neurochem. 115, 574-584.
198. Ferrer, I., Barrachina, M., Puig, B., Martínez de Lagrán, M., Martí, E., Avila, J., and Dierssen, M. (2005) Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down Syndrome, Pick disease, and related transgenic models. Neurobiol. Dis. 20, 392-400.
199. Smith, B., Medda, F., Gokhale, V., Dunckley, T., and Hulme, C. (2012) Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's? ACS Chem. Neurosci. 3, 857-872.
200. Frost, D., Meechoovet, B., Wang, T., Gately, S., Giorgetti, M., Shcherbakova, I., and Dunckley, T. (2011) β-Carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites. PLoS One 6, e19264.
201. Bain, J., McLauchlan, H., Elliott, M., and Cohen, P. (2003) The specificities of protein kinase inhibitors: an update. Biochem. J. 371, 199-204.
202. Guedj, F., Sébrié, C., Rivals, I., Ledru, A., Paly, E., Bizot, J. C., Smith, D., Rubin, E., Gillet, B., Arbones, M., and Delabar, J. M. (2009) Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A. PLoS One 4, e4606.
203. Cozza, G., M, M., Papinutto, E., Bain, J., Elliott, M., di Maira, G., Gianoncelli, A., Pagano, M. A., Sarno, S., Ruzzene, M., Battistutta, R., Meggio, F., Moro, S., Zagotto, G., and Pinna, L. A. (2009) Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2. Biochem. J. 421, 387-395.
204. Bhaskar, K., Hobbs, G. A., Yen, S. H., and Lee, G. (2010) Tyrosine phosphorylation of tau accompanies disease progression in transgenic mouse models of tauopathy. Neuropathol. Appl. Neurobiol. 36, 462-477.
205. Larson, M., Sherman, M. A., Amar, F., Nuvolone, M., Schneider, J. A., Bennett, D. A., Aguzzi, A., and Lesné, S. E. (2012) The complex PrPc-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease. J. Neurosci. 32, 16857-16871.
206. Klein, C., Krämer, E.-M., Cardine, A.-M., Schraven, B., Brandt, R., and Trotter, J. (2002) Process outgrowth of oligodendrocytes is promoted by interaction of Fyn kinase with the cytoskeletal protein tau. J. Neurosci. 22, 698-707.
207. Pooler, A., Usardi, A., Evans, C., Philpott, K., Noble, W., and Hanger, D. (2012) Dynamic association of tau with neuronal membranes is regulated by phosphorylation. Neurobiol. Aging 33, 431.
208. Bhaskar, K., Yen, S.-H., and Lee, G. (2005) Disease-related modifications in tau affect the interaction between Fyn and Tau. J. Biol. Chem. 280, 35119-35125.
209. Peters, P. J., Mironov, A., Peretz, D., van Donselaar, E., Leclerc, E., Erpel, S., DeArmond, S. J., Burton, D. R., Williamson, R. A., Vey, M., and Prusiner, S. B. (2003) Trafficking of prion proteins through a caveolae-mediated endosomal pathway. J. Cell Biol. 162, 703-717.
210. Sinha, B., Köster, D., Ruez, R., Gonnord, P., Bastiani, M., Abankwa, D., Stan, R. V., Butler-Browne, G., Vedie, B., Johannes, L., Morone, N., Parton, R. G., Raposo, G., Sens, P., Lamaze, C., and Nassoy, P. (2011) Cells respond to mechanical stress by rapid disassembly of caveolae. Cell 144, 402-413.
211. Piette, F., Belmin, J., Vincent, H., Schmidt, N., Pariel, S., Verny, M., Marquis, C., Mely, J., Hugonot-Diener, L., Kinet, J.-P., Dubreuil, P., Moussy, A., and Hermine, O. (2011) Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. Alzheimer's Res. Ther. 3, 16.
212. Nygaard, H. B., v, D. C., and Strittmatter, S. M. (2014) Fyn kinase inhibition as a novel therapy for Alzheimer's disease. Alzheimer's Res. Ther. 6, 8.
213. Yang, T., Knowles, J. K., Lu, Q., Zhang, H., Arancio, O., Moore, L. A., Chang, T., Wang, Q., Andreasson, K., Rajadas, J., Fuller, G. G., Xie, Y., Massa, S. M., and Longo, F. M. (2008) Small molecule, non-peptide p75NTR ligands inhibit Aβ-induced neurodegeneration and synaptic impairment. PLoS One 3, e3604.
214. Nguyen, T.-V.; Shen, L.; Vander Griend, L.; Quach, L. N.; Belichenko, N. P.; Saw, N.; Yang, T.; Shamloo, M.; Wyss-Coray, T.; Massa, S. M.; Longo, F. M. (2014) Small molecule p75NTR ligands reduce pathological phosphorylation and misfolding of tau, inflammatory changes, cholinergic degeneration, and cognitive deficits in AβPPL/S transgenic mice. J. Alzheimer's Dis., DOI: 10.3233/JAD-140036, in press.
215. Jolivalt, C. G., Lee, C. A., Beiswenger, K. K., Smith, J. L., Orlov, M., Torrance, M. A., and Masliah, E. (2008) Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J. Neurosci. Res. 86, 3265-3274.
216. Clodfelder-Miller, B. J., Zmijewska, A. A., Johnson, G. V. W., and Jope, R. S. (2006) Tau is hyperphosphorylated at multiple sites in mouse brain in vivo after streptozotocin-induced insulin deficiency. Diabetes 55, 3320-3325.
217. Xiong, H., Zheng, C., Wang, J., Song, J., Zhao, G., Shen, H., and Deng, Y. (2013) The neuroprotection of liraglutide on alzheimer-like learning and memory impairment by modulating the hyperphosphorylation of tau and neurofilament proteins and insulin signaling pathways in mice. J. Alzheimer's Dis. 37, 623-635.
218. Kang, M. J., Kim, C., Jeong, H., Cho, B. K., Ryou, A. L., Hwang, D., Mook-Jung, I., and Yi, E. C. (2013) Synapsin-1 and tau reciprocal O-GlcNAcylation and phosphorylation sites in mouse brain synaptosomes. Exp. Mol. Med. 45, e29.
219. Liu, F., Shi, J., Tanimukai, H., Gu, J., Gu, J., Grundke-Iqbal, I., Iqbal, K., and Gong, C.-X. (2009) Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. Brain 132, 1820-1832.
220. Lefebvre, T., Ferreira, S., Dupont-Wallois, L., Bussière, T., Dupire, M.-J., Delacourte, A., Michalski, J.-C., and Caillet-Boudin, M.-L. (2003) Evidence of a balance between phosphorylation and OGlcNAc glycosylation of tau proteins - a role in nuclear localization. Biochim. Biophys. Acta, Gen. Subj. 1619, 167-176.
221. Yu, Y., Zhang, L., Li, X., Run, X., Liang, Z., Li, Y., Liu, Y., Lee, M. H., Grundke-Iqbal, I., Iqbal, K., Vocadlo, D. J., Liu, F., and Gong, C.-X. (2012) Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation. PLoS One 7, e35277.
222. Yuzwa, S. A., Cheung, A. H., Okon, M., McIntosh, L. P., and Vocadlo, D. J. (2014) O-GlcNAc modification of tau directly inhibits its aggregation without perturbing the conformational properties of tau monomers. J. Mol. Biol. 426, 1736-1752.
223. Diwu, Y., Tian, J., and Shi, J. (2013) Effect of xixin decoction on O-linked N-acetylglucosamine glycosylation of tau proteins in rat brain with sporadic Alzheimer disease. J. Tradit. Chin. Med. 33, 367-372.
224. Fischer, P. (2008) Turning down tau phosphorylation. Nat. Chem. Biol. 4, 448-449.
225. Ko, L.-w., Ko, E. C., Nacharaju, P., Liu, W.-K., Chang, E., Kenessey, A., and Yen, S.-H. C. (1999) An immunochemical study on tau glycation in paired helical filaments. Brain Res. 830, 301-313.
226. Kuhla, B., Haase, C., Flach, K., Lüth, H.-J., Arendt, T., and Münch, G. (2007) Effect of pseudophosphorylation and cross-linking by lipid peroxidation and advanced glycation end product precursors on tau aggregation and filament formation. J. Biol. Chem. 282, 6984-6991.
227. Necula, M., and Kuret, J. (2004) Pseudophosphorylation and glycation of tau protein enhance but do not trigger fibrillization in vitro. J. Biol. Chem. 279, 49694-49703.
228. Yan, S. D., Yan, S. F., Chen, X., Fu, J., Chen, M., Kuppusamy, P., Smith, M. A., Perry, G., Godman, G. C., Nawroth, P., Zweier, J. L., and Stern, D. (1995) Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid β-peptide. Nat. Med. 1, 693-699.
229. Chen, L., Wei, Y., Wang, X., and He, R. (2009) D-Ribosylated tau forms globular aggregates with high cytotoxicity. Cell. Mol. Life Sci. 66, 2559-2571.
230. Kamah, A., Huvent, I., Cantrelle, F.-X., Qi, H., Lippens, G., Landrieu, I., and Smet-Nocca, C. (2014) Nuclear magnetic resonance analysis of the acetylation pattern of the neuronal tau protein. Biochemistry 53, 3020-3032.
231. Cook, C., Carlomagno, Y., Gendron, T. F., Dunmore, J., Scheffel, K., Stetler, C., Davis, M., Dickson, D., Jarpe, M., DeTure, M., and Petrucelli, L. (2014) Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum. Mol. Genet. 23, 104-116.
232. Xiong, Y., Zhao, K., Wu, J., Xu, Z., Jin, S., and Zhang, Y. Q. (2013) HDAC6 mutations rescue human tau-induced microtubule defects in Drosophila. Proc. Natl. Acad. Sci. U.S.A. 110, 4604-4609.
233. Fass, D. M., Reis, S. A., Ghosh, B., Hennig, K. M., Joseph, N. F., Zhao, W.-N., Nieland, T. J. F., Guan, J.-S., Groves Kuhnle, C. E., Tang, W., Barker, D. D., Mazitschek, R., Schreiber, S. L., Tsai, L.-H., and Haggarty, S. J. (2013) Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatinmediated neuroplasticity. Neuropharmacology 64, 81-96.
234. Ricobaraza, A., Cuadrado-Tejedor, M., Pérez-Mediavilla, A., Frechilla, D., Del Río, J., and García-Osta, A. (2009) Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology 34, 1721-1732.
235. Cohen, T. J., Friedmann, D., Hwang, A. W., Marmorstein, R., and Lee, V. M. Y. (2013) The microtubule-associated tau protein has intrinsic acetyltransferase activity. Nat. Struct. Mol. Biol. 20, 756-762.
236. Noack, M., Leyk, J., and Richter-Landsberg, C. (2014) HDAC6 inhibition results in tau acetylation and modulates tau phosphorylation and degradation in oligodendrocytes. Glia 62, 535-547.
237. Cohen, T. J., G, J., Hurtado, D. E., Kwong, L. K., Mills, I. P., Trojanowski, J. Q., and Lee, V. M. (2011) The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat. Commun. 2, 252.
238. Min, S.-W., Cho, S.-H., Zhou, Y., Schroeder, S., Haroutunian, V., Seeley, W. W., Huang, E. J., Shen, Y., Masliah, E., Mukherjee, C., Meyers, D., Cole, P. A., Ott, M., and Gan, L. (2010) Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67, 953-966.
239. Takahashi, K., Ishida, M., Komano, H., and Takahashi, H. (2008) SUMO-1 immunoreactivity co-localizes with phospho-tau in APP transgenic mice but not in mutant Tau transgenic mice. Neurosci. Lett. 441, 90-93.
240. Zhang, Y. J., Xu, Y. F., Chen, X. Q., Wang, X. C., and Wang, J.-Z. (2005) Nitration and oligomerization of tau induced by peroxynitrite inhibit its microtubule-binding activity. FEBS Lett. 579, 2421-2427.
241. Reynolds, M. R., Lukas, T. J., Berry, R. W., and Binder, L. I. (2006) Peroxynitrite-mediated τ modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms. Biochemistry 45, 4314-4326.
242. Kolarova, M., García-Sierra, F., Bartos, A., Ricny, J., and Ripova, D. (2012) Structure and pathology of tau protein in Alzheimer disease. Int. J. Alzheimer's Dis. 2012, 13.
243. Rissman, R. A., Poon, W. W., Blurton-Jones, M., Oddo, S., Torp, R., Vitek, M. P., LaFerla, F. M., Rohn, T. T., and Cotman, C. W. (2004) Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J. Clin. Invest. 114, 121-130.
244. Hampel, H., Bürger, K., Pruessner, J. C., Zinkowski, R., DeBernardis, J., Kerkman, D., Leinsinger, G., Evans, A. C., Davies, P., Möller, H. J., and Teipel, S. J. (2005) Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol. 62, 770-773.
245. Rapoport, M., Dawson, H. N., Binder, L. I., Vitek, M. P., and Ferreira, A. (2002) Tau is essential to beta-amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. U.S.A. 99, 6364-6369.
246. Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G. Q., and Mucke, L. (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316, 750-754.
247. Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Paul Murphy, M., Baker, M., Yu, X., Duff, K., Hardy, J., Corral, A., Lin, W. L., Yen, S. H., Dickson, D. W., Davies, P., and Hutton, M. (2000) Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25, 402-405.
248. Asuni, A. A., Boutajangout, A., Quartermain, D., and Sigurdsson, E. M. (2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci. 27, 9115-9129.
249. Boutajangout, A., Quartermain, D., and Sigurdsson, E. M. (2010) Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J. Neurosci. 30, 16559-16566.
250. Bi, M., Ittner, A., Ke, Y. D., Gotz, J., and Ittner, L. M. (2011) Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One 6, e26860.
251. Theunis, C., Crespo-Biel, N., Gafner, V., Pihlgren, M., Lopez- Deber, M. P., Reis, P., Hickman, D. T., Adolfsson, O., Chuard, N., Ndao, D. M., Borghgraef, P., Devijver, H., Van Leuven, F., Pfeifer, A., and Muhs, A. (2013) Efficacy and safety of a liposome-based vaccine against protein tau, assessed in tau.P301L mice that model tauopathy. PLoS One 8, e72301.
252. Boimel, M., Grigoriadis, N., Lourbopoulos, A., Haber, E., Abramsky, O., and Rosenmann, H. (2010) Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp. Neurol. 224, 472-485.
253. Troquier, L., Caillierez, R., Burnouf, S., Fernandez-Gomez, F. J., Grosjean, M. E., Zommer, N., Sergeant, N., Schraen-Maschke, S., Blum, D., and Buee, L. (2012) Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr. Alzheimer Res. 9, 397-405.
254. Rosenmann, H., Grigoriadis, N., Karussis, D., Boimel, M., Touloumi, O., Ovadia, H., and Abramsky, O. (2006) Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol. 63, 1459-1467.
255. Rozenstein-Tsalkovich, L., Grigoriadis, N., Lourbopoulos, A., Nousiopoulou, E., Kassis, I., Abramsky, O., Karussis, D., and Rosenmann, H. (2013) Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation. Exp. Neurol. 248, 451-456.
256. Boutajangout, A., Ingadottir, J., Davies, P., and Sigurdsson, E. M. (2011) Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J. Neurochem 118, 658-667.
257. Chai, X., Wu, S., Murray, T. K., Kinley, R., Cella, C. V., Sims, H., Buckner, N., Hanmer, J., Davies, P., O'Neill, M. J., Hutton, M. L., and Citron, M. (2011) Passive immunization with anti-tau antibodies in two transgenic models: reduction of tau pathology and delay of disease progression. J. Biol. Chem. 286, 34457-34467.
258. Walls, K. C., Ager, R. R., Vasilevko, V., Cheng, D., Medeiros, R., and LaFerla, F. M. (2014) p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice. Neurosci. Lett. 575, 96-100.
259. Yanamandra, K., Kfoury, N., Jiang, H., Mahan, T. E., Ma, S., Maloney, S. E., Wozniak, D. F., Diamond, M. I., and Holtzman, D. M. (2013) Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80, 402-414.
260. Castillo-Carranza, D. L., Sengupta, U., Guerrero-Munoz, M. J., Lasagna-Reeves, C. A., Gerson, J. E., Singh, G., Estes, D. M., Barrett, A. D., Dineley, K. T., Jackson, G. R., and Kayed, R. (2014) Passive immunization with tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J. Neurosci. 34, 4260-4272.
261. Castillo-Carranza, D. L., Gerson, J. E., Sengupta, U., Guerrero-Munoz, M. J., Lasagna-Reeves, C. A., and Kayed, R. (2014) Specific targeting of tau oligomers in htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds. J. Alzheimer's Dis 40, S97-S111.
262. Brunden, K. R.; Trojanowski, J. Q.; Smith, A. B.; Lee, V. M.; Ballatore, C. (2014) Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease.Bioorg. Med. Chem., DOI: 10.1016/j.bmc.2013.12.046, in press.
263. Shiryaev, N., Jouroukhin, Y., Giladi, E., Polyzoidou, E., Grigoriadis, N. C., Rosenmann, H., and Gozes, I. (2009) NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol. Dis. 34, 381-388.
264. Vulih-Shultzman, I., Pinhasov, A., Mandel, S., Grigoriadis, N., Touloumi, O., Pittel, Z., and Gozes, I. (2007) Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J. Pharmacol. Exp. Ther. 323, 438-449.
265. Zhang, B., Carroll, J., Trojanowski, J. Q., Yao, Y., Iba, M., Potuzak, J. S., Hogan, A.-M. L., Xie, S. X., Ballatore, C., Smith, A. B., Lee, V. M.-Y., and Brunden, K. R. (2012) The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J. Neurosci. 32, 3601-3611.
266. Matsuoka, Y., Jouroukhin, Y., Gray, A. J., Ma, L., Hirata-Fukae, C., Li, H.-F., Feng, L., Lecanu, L., Walker, B. R., Planel, E., Arancio, O., Gozes, I., and Aisen, P. S. (2008) A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J. Pharmacol. Exp. Ther. 325, 146-153.
267. Quraishe, S., C, C., and Mudher, A. (2013) NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy. Mol. Psychiatry 18, 834-842.
268. Shemesh, O. A., and Spira, M. E. (2011) Rescue of neurons from undergoing hallmark tau-induced Alzheimer's disease cell pathologies by the antimitotic drug paclitaxel. Neurobiol. Dis. 43, 163-175.
269. Erez, H., Shemesh, O. A., and Spira, M. E. (2014) Rescue of tau-induced synaptic transmission pathology by paclitaxel. Front. Cell. Neurosci. 8, 34.
270. Das, V., and Miller, J. H. (2012) Microtubule stabilization by peloruside A and paclitaxel rescues degenerating neurons from okadaic acid-induced tau phosphorylation. Eur. J. Neurosc. 35, 1705-1717.
271. Barten, D. M., Fanara, P., Andorfer, C., Hoque, N., Wong, P. Y. A., Husted, K. H., Cadelina, G. W., DeCarr, L. B., Yang, L., Liu, V., Fessler, C., Protassio, J., Riff, T., Turner, H., Janus, C. G., Sankaranarayanan, S., Polson, C., Meredith, J. E., Gray, G., Hanna, A., Olson, R. E., Kim, S.-H., Vite, G. D., Lee, F. Y., and Albright, C. F. (2012) Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027. J. Neurosci. 32, 7137-7145.
272. Brunden, K. R., Zhang, B., Carroll, J., Yao, Y., Potuzak, J. S., Hogan, A.-M. L., Iba, M., James, M. J., Xie, S. X., Ballatore, C., Smith, A. B., Lee, V. M.-Y., and Trojanowski, J. Q. (2010) Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J. Neurosci. 30, 13861-13866.
273. Brunden, K. R., Ballatore, C., Lee, V. M., Smith, A. B., 3rd, and Trojanowski, J. Q. (2012) Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. Biochem. Soc. Trans. 40, 661-666.
274. Wolfe, M. S. (2014) Targeting mRNA for Alzheimer's and related dementias. Scientifica 2014, 13.